Your browser is no longer supported. Please, upgrade your browser.
Collegium Pharmaceutical, Inc.
Index- P/E30.66 EPS (ttm)0.76 Insider Own2.60% Shs Outstand34.59M Perf Week-0.21%
Market Cap810.72M Forward P/E9.98 EPS next Y2.34 Insider Trans-16.67% Shs Float31.88M Perf Month-3.63%
Income26.80M PEG55.74 EPS next Q0.29 Inst Own- Short Float13.34% Perf Quarter3.37%
Sales310.00M P/S2.62 EPS this Y212.10% Inst Trans-0.43% Short Ratio7.17 Perf Half Y9.63%
Book/sh5.38 P/B4.34 EPS next Y51.95% ROA4.20% Target Price29.57 Perf Year27.49%
Cash/sh5.01 P/C4.66 EPS next 5Y0.55% ROE16.30% 52W Range15.66 - 26.91 Perf YTD16.48%
Dividend- P/FCF9.17 EPS past 5Y17.10% ROI12.50% 52W High-13.94% Beta1.03
Dividend %- Quick Ratio1.10 Sales past 5Y- Gross Margin58.00% 52W Low47.89% ATR1.07
Employees234 Current Ratio1.20 Sales Q/Q2.80% Oper. Margin18.20% RSI (14)44.67 Volatility3.87% 4.68%
OptionableYes Debt/Eq1.38 EPS Q/Q400.90% Profit Margin8.60% Rel Volume0.19 Prev Close23.33
ShortableYes LT Debt/Eq1.13 EarningsFeb 25 AMC Payout0.00% Avg Volume593.00K Price23.16
Recom2.10 SMA20-4.15% SMA50-4.00% SMA20013.53% Volume57,822 Change-0.73%
Jan-11-21Reiterated H.C. Wainwright Buy $29 → $33
Jul-14-20Initiated BWS Financial Sell $8
May-27-20Initiated Guggenheim Neutral
Feb-19-20Resumed Jefferies Buy $43
Oct-30-19Reiterated Needham Buy $33 → $25
May-03-19Resumed H.C. Wainwright Buy $23
Apr-12-19Resumed Janney Buy $29
Mar-20-19Initiated SunTrust Hold $22
Jan-16-19Reiterated Needham Buy $35 → $33
Mar-08-18Reiterated H.C. Wainwright Buy $21 → $33
Feb-07-18Reiterated Needham Buy $28 → $35
Dec-05-17Reiterated Needham Buy $25 → $28
Sep-11-17Initiated H.C. Wainwright Buy $21
May-11-17Reiterated Needham Buy $28 → $25
Sep-13-16Initiated Gabelli & Co Buy $25
Jun-01-15Initiated Piper Jaffray Overweight $26
Jun-01-15Initiated Needham Buy $28
Jun-01-15Initiated Jefferies Buy $20
Feb-26-21 08:01AM  
Feb-25-21 04:01PM  
Feb-24-21 10:27AM  
Feb-11-21 04:01PM  
Feb-09-21 06:31PM  
Feb-08-21 06:49PM  
Jan-06-21 04:01PM  
Dec-16-20 05:48PM  
Nov-07-20 08:36AM  
Nov-06-20 10:31PM  
Nov-05-20 05:45PM  
Oct-29-20 12:35PM  
Oct-26-20 08:00AM  
Oct-25-20 07:05AM  
Oct-22-20 04:01PM  
Oct-12-20 01:25PM  
Oct-04-20 06:51AM  
Sep-30-20 08:00AM  
Sep-25-20 08:00AM  
Sep-14-20 08:00AM  
Sep-09-20 04:05PM  
Aug-07-20 11:39AM  
Aug-05-20 07:15PM  
Aug-04-20 12:04PM  
Aug-03-20 12:59PM  
Jul-29-20 12:33PM  
Jul-21-20 05:00PM  
Jul-07-20 11:40AM  
Jun-19-20 11:40AM  
Jun-17-20 05:09PM  
Jun-03-20 11:40AM  
May-27-20 08:44AM  
May-18-20 11:40AM  
May-13-20 11:06AM  
May-08-20 12:31PM  
May-07-20 04:01PM  
Apr-30-20 12:34PM  
Apr-23-20 04:01PM  
Apr-07-20 04:01PM  
Apr-06-20 09:30AM  
Apr-01-20 08:50AM  
Mar-26-20 11:40AM  
Mar-24-20 05:03AM  
Mar-20-20 07:44AM  
Mar-10-20 11:40AM  
Feb-27-20 04:01PM  
Feb-26-20 01:05PM  
Feb-20-20 12:31PM  
Feb-13-20 04:01PM  
Feb-10-20 07:15PM  
Feb-08-20 07:04AM  
Feb-07-20 07:32AM  
Feb-06-20 04:01PM  
Jan-31-20 05:00PM  
Jan-21-20 08:41AM  
Jan-14-20 11:50AM  
Jan-09-20 08:39AM  
Jan-08-20 08:12AM  
Jan-07-20 04:05PM  
Dec-13-19 11:32AM  
Dec-10-19 05:43PM  
Dec-06-19 02:39PM  
Nov-26-19 08:01AM  
Nov-08-19 08:14AM  
Nov-06-19 06:25PM  
Oct-30-19 10:34AM  
Oct-23-19 08:00AM  
Oct-19-19 10:02AM  
Sep-26-19 04:08PM  
Sep-25-19 08:00AM  
Sep-23-19 06:00AM  
Sep-03-19 04:01PM  
Aug-29-19 04:01PM  
Aug-08-19 11:24PM  
Aug-07-19 06:35PM  
Jul-31-19 10:36AM  
Jul-24-19 04:01PM  
Jul-23-19 12:19PM  
Jun-28-19 05:03PM  
Jun-19-19 10:41AM  
May-29-19 08:00AM  
May-09-19 10:03PM  
May-08-19 05:45PM  
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Heffernan Michael ThomasDirectorMar 15Sale25.3050,0751,266,7744,047Mar 17 04:03 PM
Ciaffoni JosephPresident and CEOMar 01Option Exercise8.2248,616399,624343,075Mar 03 08:02 PM
Ciaffoni JosephPresident and CEOMar 01Sale22.6764,7681,468,425278,307Mar 03 08:02 PM
Fleming Alison BChief Technical OfficerMar 01Sale23.366,011140,417148,753Mar 03 08:01 PM
Dreyer ScottEVP & Chief Commercial OfficerFeb 11Sale25.217,898199,13283,258Feb 12 04:16 PM
Kuhlmann Shirley R.EVP and General CounselJan 20Sale24.456,081148,680103,582Jan 21 04:29 PM
Dreyer ScottEVP & Chief Commercial OfficerJan 15Sale22.891,32230,26144,395Jan 20 04:15 PM
Fleming Alison BChief Technology OfficerJan 07Option Exercise5.7316,04291,921127,461Jan 11 05:06 PM
Fleming Alison BChief Technology OfficerJan 07Sale22.0016,042352,924111,419Jan 11 05:06 PM
Fleming Alison BChief Technology OfficerDec 03Sale19.245,967114,805111,419Dec 07 04:03 PM
Fleming Alison BChief Technology OfficerNov 18Option Exercise5.7316,00091,680117,386Nov 20 04:28 PM
Kuhlmann Shirley R.EVP and General CounselOct 15Sale20.827,060146,98957,531Oct 16 04:07 PM
Heffernan Michael ThomasDirectorAug 11Sale19.1313,071250,04854,122Aug 12 04:05 PM
Dreyer ScottEVP & Chief Commercial OfficerJul 13Sale17.011,42924,30746,418Jul 14 04:06 PM
Ciaffoni JosephPresident and CEOJun 02Sale20.485,861120,058192,798Jun 02 06:58 PM
Ciaffoni JosephPresident and CEOJun 01Option Exercise8.2264,820532,820269,335Jun 02 06:58 PM
Ciaffoni JosephPresident and CEOJun 01Sale21.5370,6761,521,709198,659Jun 02 06:58 PM
Dreyer ScottEVP & Chief Commercial OfficerMay 18Option Exercise15.908,000127,20056,441May 20 04:18 PM
Dreyer ScottEVP & Chief Commercial OfficerMay 18Sale24.008,000192,00048,441May 20 04:18 PM
Fleming Alison BChief Technology OfficerMay 13Sale21.677,989173,147102,901May 15 04:16 PM
Heffernan Michael ThomasDirectorMay 13Sale21.6319,254416,42181,796May 15 04:17 PM
Dreyer ScottEVP & Chief Commercial OfficerMay 13Sale22.614,434100,25348,441May 15 04:15 PM